Navigating the Evolving Landscape of Endometrial Cancer Industry Supported Symposium

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the Navigating the Evolving Landscape of Endometrial Cancer Industry Supported Symposium presented at the 2025 SGO Annual Meeting on Women’s Cancer® on Monday, March 17, 2025.

This ninety-minute symposium will address the evolving landscape of endometrial cancer treatment, with a particular focus on an XPO1 inhibitor endometrial cancer program. As treatment strategies for advanced endometrial cancer continue to evolve, this session will explore with the currently enrolling Phase 3 trial evaluating selinexor maintenance therapy in patients with TP53 wild-type (wt) advanced/recurrent endometrial cancer.

Additionally, the latest clinical trial data will be reviewed, along with practical case studies on patients that may be eligible for the XPORT-042 study.  By the end of the session, participants will have a deeper understanding of the unmet needs in advanced endometrial cancer and the XPO1 inhibitor endometrial program, with practical insights on potentially eligible patients.

This non-promotional symposium was developed by The GOG Foundation, Inc. in partnership with Karyopharm.

Target Audience

This symposium is designed for gynecologic oncologists, medical oncologists, researchers, clinical trial coordinators, and healthcare professionals involved in the treatment and management of endometrial cancer, as well as those interested in the latest advancements in cancer therapies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:

  • Understand the proposed mechanism of action of selinexor, an XPO1 inhibitor, in EC and rationale supporting the currently enrolling EC-042 Phase 3 study
  • Understand study design of EC-042 Phase 3 study, including inclusion/exclusion criteria, and primary/secondary endpoints
  • Review real-world case studies to better understand patients that may be eligible for the EC-042 Phase 3 study

Agenda

Navigating the Evolving Landscape of Endometrial Cancer, an Industry Supported Symposium presented at the 2025 SGO Annual Meeting on Women’s Cancer®

 

Presented on Monday, March 17, 2025

This enduring education will be available on the GOG website for six months after the live presentation.

View Recording

View Presentation

Welcome & Introductions
Kathleen Moore, MD
Current Endometrial Cancer Treatment Landscape and Role of Molecular Profiling in Targeted Treatments for Endometrial Cancer
Linda Duska, MD, MPH
Rationale for Investigating Selinexor, an XPO1 inhibitor, in Advanced/Recurrent Endometrial Cancer
Scott Jordan, MD
Clinical Trial Design of the Currently Enrolling EC-042 Phase 3 Study
Kathleen Moore, MD
Case-Based Studies and Interactive Discussion
All Faculty
Closing Remarks
Kathleen Moore, MD
Selinexor is not approved and its safety and efficacy have not been established in endometrial cancer